The advancements in Early-Onset Alzheimer's Disease (EOAD) diagnostic tools, such as blood-based biomarkers and smartphone-based assessments, raise important ethical and social considerations. Ethically, the use of blood-based biomarkers for EOAD diagnosis may lead to concerns regarding privacy, consent, and the potential for discrimination based on genetic predispositions. Safeguarding patient data and ensuring informed consent for genetic testing are essential to uphold ethical standards in utilizing these diagnostic tools.
From a social perspective, the availability of blood-based biomarkers and smartphone-based assessments for EOAD may impact individuals' perceptions of genetic risk and disease susceptibility. This could lead to psychological distress, stigmatization, or altered family dynamics. Healthcare providers must offer comprehensive counseling and support services to address the emotional and social implications of EOAD diagnosis based on these advanced tools. Additionally, ensuring equitable access to these diagnostic technologies is crucial to prevent disparities in healthcare delivery and outcomes among diverse populations.